Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 21 Parkinson's papers of 1,548 | 0.59 |
| pathways Reactome | 5 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 14808
Sealed predictions
- GRK2 in dopamine neurons, braak-0.65 (p 0.059) → -0.48 (p 0.190)receipt 14815
Swarm cases
receipt 14815: GRK2 in dopamine neurons, braak
- power
- full sample -0.53 (p 0.024, n 18), 95% CI -0.80 to -0.08. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.52 (p 0.027, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.60 (p 0.0083, n 18). not the mix.
- skeptic
- leave-one-out range -0.64 to -0.47, sign flips 0; without severely affected donors -0.53 (p 0.024, n 18). robust.
- cell type
- strongest in OPCs: -0.65 (p 0.0036, n 18) vs -0.53 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GRK2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GRK2 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.35 p 0.214 (needs p < 1.6e-4)
Receipts
loading the receipts